An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).
Patients with advanced hepatocellular carcinoma and high tumour burden (Vp4 PVTT, Vp3 PVTT with bilateral involvement, >50% liver involvement) have poor outcomes and are under-represented in major hepatocellular carcinoma trials (1,2). HAIC has been widely studied in Asian population, with positive results especially in patients with high tumour burden but is not validated in Western population.
Patients with advanced hepatocellular carcinoma and high tumour burden (Vp4 PVTT, Vp3 PVTT with bilateral involvement, >50% liver involvement) have poor outcomes and are under-represented in major hepatocellular carcinoma trials (1,2). HAIC has been widely studied in Asian population, with positive results especially in patients with high tumour burden but is not validated in Western population.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Dig Liver Dis
Why it surfaced
Matched watchlist topic 'Novel therapeutics: immunotherapy, CAR-T, targeted therapy'. Study design: Randomized Controlled Trial (inferred). Score: 8/10 (N:1, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.